[Treatment of XXXX with @entity170 and @entity134 -induced @entity170 with the preparation Rocaltrol (1,25/OH/2 vitamin D3)].

@entity1 @entity170 @entity3814 @entity134 @entity460 @entity3151
A clinical trial of the drug "Rocaltrol" was carried out on 16 @entity1 with @entity170 , II of them with menopause @entity170 and 5 with @entity134 -induced @entity170 . The mean age of the @entity1 was 53.1 +/- 11.1 years. The mean daily dose of the drug was 0.46 +/- 0.08 mg/24h. The treatment lasted 6 months. All @entity1 showed improvement of the general condition and of @entity460 balance. Reliable increase of the total @entity460 and @entity3151 levels and of the 24-hour @entity460 urine excretion were established, the maximal values being at the end of the third month. The X-ray examination showed stabilization of the bone changes and lack of new @entity3814 . It is supposed that the drug improves the intestinal resorption of @entity460 and @entity3151 and suppresses the bone resorption. This is proved by the reliable decrease of serum alkaline phosphatase level after the 6 month treatment. In all @entity1 clinical improvement was established with diminishing of the bone aches and retaining the body height before and after the treatment.
